Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | ALKBH3 | Q96Q83 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7969172 | 0.83 | NPC1 (0.53) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7962507 | 0.83 | NPY5R (0.60) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7973223 | 0.80 | NPY5R (0.62) | NPY5RADRA1AKCNH2ALKBH3 | |
| SCHEMBL7970001 | 0.80 | GFER (0.56) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7962503 | 0.80 | NPY5R (0.52) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7973969 | 0.79 | CHEK2 (0.57) | NPY5R | |
| SCHEMBL7976233 | 0.78 | PRSS1 (0.52) | NPY5R | |
| SCHEMBL3791087 | 0.76 | NPC1 (0.47) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7973178 | 0.74 | NPY5R (0.56) | MEN1KMT2ANPY5RMAPTKDM4E | |
| SCHEMBL3787151 | 0.73 | MEN1 (0.44) | MEN1NPC1RAB9AKMT2ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | MEN1 994/4885NPC1 1029/4885RAB9A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.